# EDGAR Filing Document

**Accession Number:** 0001501756
**File Stem:** 0001311210-25-000004
**Filing Date:** 2025-12
**Character Count:** 10414
**Document Hash:** 7fb42b9b0a0fc42436ae89c1da58a8b8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001311210-25-000004.hdr.sgml**: 20251210

**ACCESSION NUMBER**: 0001311210-25-000004

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251209

**FILED AS OF DATE**: 20251210

**DATE AS OF CHANGE**: 20251210

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Machado Patrick
- **CENTRAL INDEX KEY:** 0001311210

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36579
- **FILM NUMBER:** 251561461

**MAIL ADDRESS:**
- **STREET 1:** 201 SPEAR STREET, 3RD FLOOR
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94107

**FORMER NAME:**
- **FORMER CONFORMED NAME:** Machado Clarence Patrick
- **DATE OF NAME CHANGE:** 20041210
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Adverum Biotechnologies, Inc.
- **CENTRAL INDEX KEY:** 0001501756
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 205258327
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 100 CARDINAL WAY
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94063
- **BUSINESS PHONE:** (650) 649-1004

**MAIL ADDRESS:**
- **STREET 1:** 100 CARDINAL WAY
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94063

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Avalanche Biotechnologies, Inc.
- **DATE OF NAME CHANGE:** 20100921

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[x] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Machado Patrick<br><sub>(Last) (First) (Middle)</sub><br>C/O ADVERUM BIOTECHNOLOGIES, INC.<br>100 CARDINAL WAY<br><sub>(Street)</sub><br>REDWOOD CITY, CA 94063<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-12-09 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Adverum Biotechnologies, Inc. [ ADVM ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-12-09 |  | U<sup>(1)(2)</sup> |  | 8818 | D | <sup>(1)(2)</sup> | 0 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | $64 | 2025-12-09 |  | D |  |  | 1000 | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 1000 | <sup>(3)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $27.50 | 2025-12-09 |  | D |  |  | 6476 | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 6476 | <sup>(3)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $27.50 | 2025-12-09 |  | D |  |  | 3360 | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 3360 | <sup>(3)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $62.50 | 2025-12-09 |  | D |  |  | 3500 | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 3500 | <sup>(3)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $134.10 | 2025-12-09 |  | D |  |  | 4500 | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 4500 | <sup>(3)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $115.20 | 2025-12-09 |  | D |  |  | 1500 | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 1500 | <sup>(3)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $256.40 | 2025-12-09 |  | D |  |  | 3000 | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 3000 | <sup>(3)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $37 | 2025-12-09 |  | D |  |  | 5250 | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 5250 | <sup>(3)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $9.90 | 2025-12-09 |  | D |  |  | 5250 | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 5250 | <sup>(3)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $15.60 | 2025-12-09 |  | D |  |  | 5250 | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 5250 | <sup>(3)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $7.32 | 2025-12-09 |  | D |  |  | 13820 | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 13820 | <sup>(3)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $2.32 | 2025-12-09 |  | D |  |  | 13590 | <sup>(4)</sup> | <sup>(4)</sup> | Common Stock | 13590 | <sup>(4)</sup> | 0 | D |  |

---

### Footnotes:

(1) In connection with the terms of an Agreement and Plan of Merger, dated as of October 24, 2025 (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's direct wholly owned subsidiary, Flying Tigers Acquisition Corporation ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $3.56 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR"), which represents the contractual right to receive up to two contingent cash payments of up to an aggregate of $8.91 per CVR, net to the stockholder in cash,

(2) (continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of both specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement") with Computershare Inc. and its affiliate, Computershare Trust Company, N.A, as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of December 9, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time").

(3) Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time.

(4) Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option granted under a Company Equity Plan having an exercise price less than the Cash Consideration (each such option, a "Cash-Out Stock Option") that was outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, and in exchange for such cancellation, the holder of such Cash-Out Stock Option received (i) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting).

**Signature:** /s/ Aneta Fergson, Attorney-in-Fact  
**Date:** 2025-12-10

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**